←RETURN TO 2026 IPO RADAR DECK (135 OFFERINGS)COHORT STANDING: #69 of 135
Verified SEC Filing/Calendar Year 2026
NASDAQHealth Care
$TRXB
RANGE-BOUND (-50% to +50%)

TRex Bio, Inc.

OFFER PRICE$14.00
CURRENT PRICE
$14.85
CUMULATIVE RETURN
+0.10%
PRICING DATE: 10/09/26OFFLINE SNAPSHOT
SECTION 01 // FORENSIC TEARDOWN

The Seagull Executive Verdict

SURVIVAL RATING: WINNER
WHAT THE BUSINESS DOES

Develops immunological therapies by targeting regulatory T-cells to treat autoimmune diseases. Generates zero commercial revenue.

THE WALL STREET PITCH

Innovative platform mapping tissue-specific regulatory T-cell behavior to conquer complex autoimmune diseases.

THE COLD REALITY

Immense timeline and capital intensity required to move novel immunological therapies through the FDA gauntlet.

SECTION 02 // CAPITAL ALLOCATION

Capital Formation & Float Scarcity

FLAG: TREASURY GROWTH
Gross Proceeds
$116.2M
Cash extracted from market
Post-Money Value
$645.0M
Total company valuation
Public Float %
18%
Shares available to public
Secondary Share %
0%
Insider cash extraction
CAPITAL USE ANALYSIS

Proceeds directed to balance sheet and operations.

SECTION 03 // SUPPLY SHOCK AUDITOR

Insider Lock-Up Expiration

VC DUMP RISK: MODERATE
Expiration Calendar Date
2027-04-07
165 DAYS REMAINING
Supply Shock Multiplier
4.2x
Float expansion ratio upon unlock
Lockup Duration
180 Days
Contractual restriction window
RESTRICTED INSTITUTIONAL HOLDERS & PRE-IPO INSIDERS
Venture Capital Syndicate

Insiders hold locked shares subject to release on 2027-04-07.

SECTION 04 // SYNDICATE TELEMETRY

Underwriter Syndicate & Fee Extraction

SPREAD: 7.00%
Gross Underwriting Spread
7.00%
Standard Wall Street fee cut
Estimated Syndicate Take
$8.1M
Total fees stripped from deal
Fee Per Public Share
$0.98
Direct cut per share printed
LEAD BOOKRUNNERS & JOINT MANAGERS
J.P. MorganEvercore ISIStifelWedbushBarclaysCitiWells Fargo Securities
SECTION 05 // COHORT BENCHMARK

Sector Peer & Cohort Telemetry

RANK: #69 of 135
2026 Cohort Standing
#69 of 135
Out of 135 total 2026 IPO offerings
Sector Median Return
+21.64%
Health Care sector midpoint
Sector Win Rate
78%
% of peer IPOs trading in profit
PERFORMANCE VS PEERS

TRex Bio, Inc. is currently trading below the Health Care sector median of 21.64%. Across the entire 2026 calendar year cohort, only 78% of Health Care offerings have sustained a positive return above their initial offer price.

SECTION 06 // PRIMARY REGULATORY PROVENANCE

SEC Filings & Works Cited

FORM 424B4 // FINAL PROSPECTUS

The legal contract codifying offer pricing, gross underwriting spread, and lock-up terms.

Available via SEC EDGAR Search
FORM S-1 / S-1A // REGISTRATION STATEMENT

Initial company disclosure detailing capitalization structure, risk factors, and financial statements.

Available via SEC EDGAR Search
WORKS CITED (MLA 9TH EDITION)

TRex Bio, Inc.. "Form 424B4 Prospectus." U.S. Securities and Exchange Commission, 10/09/26, www.sec.gov/edgar.

United States, Securities and Exchange Commission. “EDGAR System Search & Research Database.” SEC.gov, 2026, www.sec.gov/edgar/searchedgar/companysearch.

← EXPLORE FULL 2026 IPO DECKBACK TO TOP ↑
TELEMETRY
BITCOIN SPOT: $84,471 [▲ 0.42%]///GOLD SPOT: $4,321.20/oz [▲ 0.54%]///SILVER SPOT: $64.80/oz [▲ 1.25%]///S&P 500: 7,743.41 [▲ 0.51%]///U.S. DEBT: $40.07T [■ Treasury]///10Y YIELD: 5.18% [▲ 0.43%]///BITCOIN SPOT: $84,471 [▲ 0.42%]///GOLD SPOT: $4,321.20/oz [▲ 0.54%]///SILVER SPOT: $64.80/oz [▲ 1.25%]///S&P 500: 7,743.41 [▲ 0.51%]///U.S. DEBT: $40.07T [■ Treasury]///10Y YIELD: 5.18% [▲ 0.43%]///BITCOIN SPOT: $84,471 [▲ 0.42%]///GOLD SPOT: $4,321.20/oz [▲ 0.54%]///SILVER SPOT: $64.80/oz [▲ 1.25%]///S&P 500: 7,743.41 [▲ 0.51%]///U.S. DEBT: $40.07T [■ Treasury]///10Y YIELD: 5.18% [▲ 0.43%]///